Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 combination therapy in resectable NSCLC
NCT07229729Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07229729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229729.